| Literature DB >> 34485488 |
Hamida van Staaden1, Candice Hendricks1, Kevin Spicer2.
Abstract
BACKGROUND: Neonatal sepsis is an important cause of mortality and morbidity in neonatal intensive care populations worldwide. Data on rates of bacteraemia and antibiotic resistance patterns are limited, particularly in the developing world.Entities:
Keywords: antibiotic resistance; antimicrobial resistance; culture collection processes; neonatal sepsis; positive blood cultures
Year: 2021 PMID: 34485488 PMCID: PMC8377790 DOI: 10.4102/sajid.v36i1.195
Source DB: PubMed Journal: S Afr J Infect Dis ISSN: 2312-0053
FIGURE 1Study population.
Comparison of organisms in demographic groups.
| Variable | Organism recovered | Total patients | % | |||||
|---|---|---|---|---|---|---|---|---|
| Gram-positive bacterium | Gram-negative bacterium | Fungus | ||||||
|
| % |
| % |
| % | |||
|
| ||||||||
| Male | 20 | - | 38 | - | 7 | - | 65 | 54.6 |
| Female | 12 | - | 28 | - | 1 | - | 41 | 34.4 |
| Unknown | 3 | - | 10 | - | 0 | - | 13 | 10.9 |
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
| 0–3 | 7 | - | 10 | - | 0 | - | 17 | 14.3 |
| 4–7 | 7 | - | 19 | - | 1 | - | 27 | 22.7 |
| 8–28 | 10 | - | 33 | - | 7 | - | 50 | 42.0 |
| 28+ | 11 | - | 14 | - | 0 | - | 25 | 21.0 |
|
|
|
|
|
|
|
|
|
|
Note: The sex was unknown in 13 (10.9%) patients and more positive cultures were obtained from males. Infants ranged in age from 0 to 84 days. The median age was 14 days.
Early onset versus late onset sepsis.
| Organism subtype |
| Total | |
|---|---|---|---|
| EOS (≤ 3 days old) | LOS (> 3 days old) | ||
|
| |||
| - | - | - | |
|
| 0 | 1 | 1 |
|
| 2 | 8 | 10 |
|
| 3 | 12 | 15 |
| - | - | - | |
|
| 0 | 2 | 2 |
|
| 2 | 5 | 7 |
|
| |||
| - | - | - | |
|
| 0 | 4 | 4 |
|
| 7 | 39 | 46 |
| 0 | 10 | 10 | |
| - | - | - | |
|
| 1 | 1 | 2 |
|
| 1 | 3 | 4 |
| Enterobacter species ( | - | - | - |
|
| 0 | 1 | 1 |
|
| 0 | 2 | 2 |
| 0 | 3 | 3 | |
| 0 | 2 | 2 | |
| 1 | 0 | 1 | |
| 0 | 1 | 1 | |
|
| |||
| - | - | - | |
|
| 0 | 1 | 1 |
|
| 0 | 1 | 1 |
|
| 0 | 1 | 1 |
|
| 0 | 5 | 5 |
|
| |||
|
|
|
|
|
, 14.3%;
, 85.7%.
EOS, early onset sepsis; LOS, late onset sepsis.
Antibiotic susceptibility for all isolates.†
| Variable | Total | Amik | Co-tri | Cephalo 2nd gen | Cepha 3rd gen | Cepha 4th gen | Clinda | Cipro | Clox | Colis | Erythro | Flucon | Genta | Pen | Pip – Taz | Vanco | Pen + Genta | T+A | Carba | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| % |
| % |
| % |
| % |
| % |
| % |
| % |
| % |
| % |
| % |
| % |
| % |
| % |
| % |
| % | ||
|
| |||||||||||||||||||||||||||||||||||||
| 11 | NT | - | 4 | 36 | NT | - | NT | - | NT | - | 2 | 18 | 9 | 82 | 1 | 9 | NT | - | 1 | 9 | NT | - | 1 | 9 | NT | - | NT | - | 11 | 100 | 1 | 9 | NT | - | NT | - | |
|
| 15 | NT | - | 14 | 94 | NT | - | NT | - | NT | - | 2 | 13 | 14 | 93 | 3 | 20 | NT | - | 2 | 13 | NT | - | 4 | 27 | NT | - | NT | - | 15 | 100 | 4 | 27 | NT | - | NT | - |
| Enterococcus | 9 | NT | - | 0 | - | NT | - | NT | - | NT | - | 0 | - | 7 | 78 | NT | - | NT | - | 5 | 55 | NT | - | 4 | 45 | 5 | 55 | NT | - | 9 | 100 | 5 | 55 | NT | - | NT | - |
|
| |||||||||||||||||||||||||||||||||||||
|
| 50 | 50 | 100 | 16 | 32 | 8 | 16 | 10 | 20 | 41 | 82 | NT | - | 40 | 80 | NT | - | 50 | 100 | NT | - | NT | - | 17 | 34 | 0 | - | 39 | 78 | NT | - | 17 | 34 | 50 | 100 | 50 | 100 |
|
| 10 | 10 | 100 | 10 | 100 | 0 | - | 7 | 70 | 7 | 70 | NT | - | 10 | 100 | NT | - | 0 | - | NT | - | NT | - | 7 | 70 | NT | - | 9 | 90 | NT | - | 7 | 70 | 10 | 100 | 10 | 100 |
|
| 6 | 3 | 50 | 1 | 17 | 1 | 17 | 2 | 33 | 2 | 33 | NT | - | 3 | 50 | NT | - | 6 | 100 | NT | - | NT | - | 3 | 50 | 0 | - | 1 | 17 | NT | - | 3 | 50 | 3 | 50 | 3 | 50 |
| Enterobacter | 3 | 3 | 100 | 2 | 66 | 0 | - | 2 | 66 | 3 | 100 | NT | - | 3 | 100 | NT | - | 3 | 100 | NT | - | NT | - | 2 | 66 | 0 | - | 2 | 66 | NT | - | 2 | 66 | 3 | 100 | 3 | 100 |
|
| 3 | 3 | 100 | 2 | 66 | 2 | 66 | 2 | 66 | 2 | 66 | NT | - | 2 | 66 | NT | - | 3 | 100 | NT | - | NT | - | 3 | 100 | 2 | 66 | 3 | 100 | NT | - | 3 | 100 | 3 | 100 | 3 | 100 |
|
| 2 | 0 | - | 1 | 50 | NT | - | 1 | 50 | 1 | 50 | NT | - | 1 | 50 | NT | - | NT | - | NT | - | NT | - | 0 | - | NT | - | 0 | - | NT | - | 0 | - | 0 | - | 0 | - |
|
| 1 | 1 | 100 | 0 | - | 1 | 100 | 1 | 100 | 1 | 100 | NT | - | 1 | 100 | NT | - | 0 | - | NT | - | NT | - | 1 | 100 | 0 | - | 1 | 100 | 0 | - | 1 | 100 | 1 | 100 | 1 | 100 |
|
| 1 | NT | - | 0 | - | 1 | 100 | NT | - | NT | - | NT | - | 1 | 100 | NT | - | NT | - | NT | - | NT | - | NT | - | 1 | 100 | 1 | 100 | NT | - | 1 | 100 | NT | - | NT | - |
|
| |||||||||||||||||||||||||||||||||||||
| 8 | NT | - | NT | - | NT | - | NT | - | NT | - | NT | - | NT | - | NT | - | NT | - | NT | - | 8 | 100 | NT | - | NT | - | NT | - | NT | - | NT | - | NT | - | NT | - | |
, Formula to calculate n (%): S/(S+R). R is number of resistant isolates and S is the number of susceptible isolates.
NT, not tested; Amik, amikacin; Co-tri, co-trimoxazole; Cephalo, cephalosporins; Clinda, clindamycin; Clox, cloxacillin; Colis, colistin; Erythro, erythromycin; Flucon, fluconazole; Genta, gentamycin; Pen, penicillin; Pip-Taz, piperacillin-tazobactam; Vanco, vancomycin.